Elevated C-Reactive Protein Is Associated With Increased Risk of Mortality From Lung Cancer in the United States

PurposeIt remains unclear if inflammation itself may induce cancer, if inflammation is a result of tumor growth, or a combination of both exists. The aim of this study was to examine whether C-reactive protein (CRP) levels and CRP gene variations were associated with an altered risk of colorectal, lung, breast, or prostate cancer.Patients and MethodsA total of 7,017 participants age ≥ 55 years from the Rotterdam Study were eligible for analyses. Mean follow-up time was 10.2 years. High-sensitivity CRP measurements were performed to identify additional values of 0.2 to 1.0 mg/L compared with standard procedures. Genotypes of the CRP gene were determined with an allelic discrimination assay.ResultsHigh levels (> 3 mg/L) of CRP were associated with an increased risk of incident cancer (hazard ratio, 1.4; 95% CI, 1.1 to 1.7) compared with persons with low levels (< 1 mg/L), even after a potential latent period of 5 years was introduced. Although CRP seems to affect several cancer sites, the association was strongest for lung cancer (hazard ratio, 2.8; 95% CI, 1.6 to 4.9). A CRP single nucleotide polymorphism associated with decreased CRP levels was associated with an increased lung cancer risk of 2.6 (95% CI, 1.6 to 4.4) in homozygous carriers.ConclusionBaseline CRP levels seem to be a biomarker of chronic inflammation preceding lung cancer, even after subtracting a 5-year latent period. Furthermore, CRP gene variation associated with low CRP blood levels was relatively common in patients with lung cancer. Both chronic inflammation and impaired defense mechanisms resulting in chronic inflammation might explain these results.

Download Full-text

Effect of Systemic Glucocorticoids on Mortality or Mechanical Ventilation in Patients With COVID-19

Journal of Hospital Medicine ◽

10.12788/jhm.3497 ◽

2020 ◽

Vol 15 (8) ◽

pp. 489-493 ◽

Cited By ~ 17

Author(s):

Marla J Keller ◽

Elizabeth A Kitsis ◽

Shitij Arora ◽

Jen-Ting Chen ◽

Shivani Agarwal ◽

...

Keyword(s):

Mechanical Ventilation ◽

Randomized Clinical Trials ◽

Hospital Medicine ◽

C Reactive Protein ◽

Glucocorticoid Treatment ◽

Reactive Protein ◽

Risk Of Mortality ◽

Increased Risk ◽

Early Use ◽

Systemic Glucocorticoids

The efficacy of glucocorticoids in COVID-19 is unclear. This study was designed to determine whether systemic glucocorticoid treatment in COVID-19 patients is associated with reduced mortality or mechanical ventilation. This observational study included 1,806 hospitalized COVID-19 patients; 140 were treated with glucocorticoids within 48 hours of admission. Early use of glucocorticoids was not associated with mortality or mechanical ventilation. However, glucocorticoid treatment of patients with initial C-reactive protein (CRP) ≥20 mg/dL was associated with significantly reduced risk of mortality or mechanical ventilation (odds ratio, 0.23; 95% CI, 0.08- 0.70), while glucocorticoid treatment of patients with CRP <10 mg/dL was associated with significantly increased risk of mortality or mechanical ventilation (OR, 2.64; 95% CI, 1.39-5.03). Whether glucocorticoid treatment is associated with changes in mortality or mechanical ventilation in patients with high or low CRP needs study in prospective, randomized clinical trials. Journal of Hospital Medicine 2020;15:XXX-XXX. © 2020 Society of Hospital Medicine

Download Full-text

C-reactive protein to albumin ratio is associated with increased risk of mortality in COVID-19 pneumonia patients

Cukurova Medical Journal ◽

10.17826/cumj.977050 ◽

2021 ◽

Vol 46 (4) ◽

pp. 1449-1458

Author(s):

Selen ACEHAN ◽

Müge GÜLEN ◽

Cem ISİKBER ◽

Adem KAYA ◽

Nurdan UNLU ◽

...

Keyword(s):

C Reactive Protein ◽

Albumin Ratio ◽

Reactive Protein ◽

Risk Of Mortality ◽

Increased Risk

Download Full-text

C-reactive protein gene 1846C>T polymorphism is associated with increased risk and clinical features of lung cancer: a case–control study

Bioscience Reports ◽

10.1042/bsr20181936 ◽

2019 ◽

Vol 39 (6) ◽

Cited By ~ 2

Author(s):

Chen Chen ◽

Jing-Ni Liu ◽

Jian-Qiang Zhao ◽

Bao Zang

Keyword(s):

Lung Cancer ◽

Case Control Study ◽

Case Control ◽

Lung Carcinogenesis ◽

C Reactive Protein ◽

Chinese Han ◽

Reactive Protein ◽

Potential Marker ◽

Increased Risk ◽

Control Study

AbstractChronic inflammation plays an important role in lung carcinogenesis. Recently, several studies investigated the association of C-reactive protein (CRP) gene 1846C>T polymorphism and lung cancer (LC) risk, but with conflicting findings. In the present study, we conducted this case–control study with 408 LC patients and 472 healthy controls in a Chinese Han population. Genotyping was performed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLR) method. Our data found that CRP gene 1846C>T polymorphism increased the risk of LC. Subgroup analyses obtained significant associations among the groups of males, ≥50 years old, smoking, and non-drinkers. Bioinformatics analysis showed that the expression levels of CRP in LC tissues were significantly increased compared with normal tissues. Additionally, the present study found CRP mRNA high expression was associated with worse survival in LC patients. Furthermore, our data indicated that TT genotype of 1846C>T polymorphism was associated with a larger size of tumor and was related with lymphatic metastasis in LC patients. In conclusion, the present study suggests that CRP gene 1846C>T polymorphism is associated with increased risk of LC. CRP gene 1846C>T polymorphism may be a potential marker for the diagnosis of LC.

Download Full-text